Every law firm that pursues aggressive growth eventually confronts the same uncomfortable tension between expanding its reach and protecting what made it worth growing in the first place. Scott Rahn, Founding Partner
New research from Bausch + Lomb has found that dry eye disease remains one of the least recognised conditions affecting women during and after menopause. The survey highlights a significant gap in
More
The legal battle between Blake Lively and Justin Baldoni has concluded through settlement, but not before producing a significant court ruling with real consequences for employers. U.S. District Judge Lewis J. Liman
More
Legal observers have drawn sharp attention to a growing question about whether executive overreach can go unchallenged when no party holds legal standing to sue. Critics argue the Supreme Court’s own standing
More
DigitalBridge has announced its intention to voluntarily delist its preferred stock from the New York Stock Exchange, marking a notable shift in the company’s capital markets strategy. The decision represents a significant
More
Frasers Group (FRAS) has been publicly censured by the UK’s advertising watchdog after a Sports Direct promotion was found to mislead shoppers over the true value of a discount. The Advertising Standards
More
Meeting the legal requirements of DSCSA and building genuine operational efficiency are two very different things, according to a senior industry figure. Gregg Gorniak, vice president of manufacturer operations and data services
More
The United States Court of Appeals for the Ninth Circuit has ruled that sports event contracts offered on prediction market exchanges are not “swaps” under the Commodity Exchange Act. The August 28,
More
At ILTACON 2026 in Nashville, the dominant theme was unmistakable: legal technology vendors are partnering with one another at an unprecedented pace. The conference’s host city made its presence felt immediately, with
More
Equity markets on Wall Street came under pressure as rising oil prices and a broad bond sell-off combined to drag stocks lower across major indices. The dual headwinds rattled investor confidence, with
More
Novartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor
More